Docoh
Loading...

37 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
INFORMATION Purpose of the Meeting About the Annual Meeting PROPOSAL NO. 1 ELECTION OF DIRECTORS CORPORATE GOVERNANCE EXECUTIVE COMPENSATION PROPOSAL NO. 2 … Annual Report on Form 10-K and our other filings with the Securities and Exchange Commission as well as our corporate governance and other related
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent and that audit committee members … nominating and corporate governance committee satisfy the independence standards for such committees established by the SEC and the Nasdaq Marketplace
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and strengthening certain review processes. During the second half of 2020, we implemented additional internal controls, including improving our corporategovernance; creating a disclosure committee; expanding review and monitoring procedures; and improving documentation of our policies and procedures
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
of a listed company’s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also … and corporate governance committee satisfy the independence standards for such committees established by the SEC and the Nasdaq Marketplace Rules
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
serve on our audit committee, our compensation committee, and our nominating and corporate governance committee satisfy the independence standards … and corporate governance committee is “independent” as defined in the applicable Nasdaq Listing Rules. The nominating and corporate governance committee’s
S-1/A
no2nt
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-3.2
bz53k8mjff 46yh
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
pqvqarldqoi k893md0m
17 Jul 20
IPO registration (amended)
5:25pm
10-K
nwnoox
5 Mar 20
Annual report
7:00pm
S-1
1sb xqcmz
13 Dec 19
IPO registration
5:32pm
DEF 14A
r4o0sg
26 Apr 19
Definitive proxy
5:02pm
10-K/A
evcvnt6xzh4zi0ul2bw
5 Apr 19
Annual report (amended)
9:40pm
10-K
hxw4idxjfi6jglk19
28 Mar 19
Annual report
5:25pm
424B3
d1sszmnqu de
13 Nov 18
Prospectus supplement
9:39pm
10-Q
itaesg 9iw00ydr79jb
13 Nov 18
Quarterly report
9:37pm
424B3
o0th1et7asah4ko
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
bgsuo14nqcxbf5
30 Oct 18
IPO registration (amended)
4:19pm
S-1/A
8e6 cez53yx6
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
a8j2w7hjar69mqeg
13 Sep 18
IPO registration (amended)
8:00pm
S-1
f00f7z 3kur7rp30ndj5
29 Jul 18
IPO registration
8:00pm